Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: Design of a multicenter randomized clinical trial

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Wevers, Marijke R ^a,b   Ausems, Margreet G E M ^b   Verhoef, Senno ^a   Bleiker, Eveline M A ^a   Hahn, Daniela E E ^a   Hogervorst, Frans B L ^a   van der Luijt, Rob B ^b   Valdimarsdottir, Heiddis B ^c   van Hillegersberg, Richard ^b   Rutgers, Emiel J ^a   Aaronson, Neil K ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ATTITUDE TO ILLNESS; BREAST CANCER; CANCER RISK; FAMILIAL CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HEALTH BEHAVIOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTICENTER STUDY; ONCOGENE; PATIENT DECISION MAKING; PATIENT SATISFACTION; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOCIAL STRESS; TUMOR SUPPRESSOR GENE; ADULT; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; MIDDLE AGED; MUTATION; PATIENT EDUCATION; PSYCHOLOGICAL ASPECT; RISK REDUCTION;

BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FOLLOW-UP STUDIES; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MASTECTOMY; MIDDLE AGED; MUTATION; PATIENT EDUCATION AS TOPIC; RISK REDUCTION BEHAVIOR;

EID: 78650997026     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-6     Document Type: Article

References (56)

1. Turnbull C, Hodgson S. Genetic predisposition to cancer. Clin Med 2005, 5:491-498.
2. Vasen HF, Tesfay E, Boonstra H, Mourits MJ, Rutgers E, Verheyen R, Oosterwijk J, Beex L. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 2005, 41:549-554. 10.1016/j.ejca.2004.10.029, 15737559.
3. Evans DG, Lalloo F, Hopwood P, Maurice A, Baildam A, Brain A, Barr L, Howell A. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol 2005, 31:1112-1118. 10.1016/j.ejso.2005.05.007, 16005602.
4. van der Hout AH, van den Ouweland AM, van der Luijt RB, Gille HJ, Bodmer D, Bruggenwirth H, Mulder IM, van der Vlies P, Elfferich P, Huisman MT, ten Berge AM, Kromosoeto J, Jansen RP, van Zon PH, Vriesman T, Arts N, Lange MB, Oosterwijk JC, Meijers-Heijboer H, Ausems MG, Hoogerbrugge N, Verhoef S, Halley DJ, Vos YJ, Hogervorst F, Ligtenberg M, Hofstra RM. A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting. Hum Mutat 2006, 27:654-666. 10.1002/humu.20340, 16683254.
5. Eccles DM. Identification of personal risk of breast cancer: genetics. Breast Cancer Res 2008, 10(Suppl 4):S12. 10.1186/bcr2172, 2614838, 19128425.
6. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56:265-271. 1801337, 7825587.
7. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005, 23:1656-1663. 10.1200/JCO.2005.10.035, 15755973.
8. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004, 22:2328-2335. 10.1200/JCO.2004.04.033, 15197194.
9. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2009, 27:5887-5892. 10.1200/JCO.2008.19.9430, 19858402.
10. Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C. Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002, 20:514-520. 10.1200/JCO.20.2.514, 11786581.
11. Braithwaite D, Emery J, Walter F, Prevost AT, Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004, 96:122-133. 10.1093/jnci/djh017, 14734702.
12. Peshkin BN, DeMarco TA, Brogan BM, Lerman C, Isaacs C. BRCA1/2 testing: complex themes in result interpretation. J Clin Oncol 2001, 19:2555-2565.
13. Peshkin BN, Isaacs C. Evaluation and management of women with BRCA1/2 mutations. Oncology (Williston Park) 2005, 19:1451-1459.
14. Pieterse AH, Ausems MG, Van Dulmen AM, Beemer FA, Bensing JM. Initial cancer genetic counseling consultation: change in counselees' cognitions and anxiety, and association with addressing their needs and preferences. Am J Med Genet A 2005, 137:27-35.
15. Rantala J, Platten U, Lindgren G, Nilsson B, Arver B, Lindblom A, Brandberg Y. Risk perception after genetic counseling in patients with increased risk of cancer. Hered Cancer Clin Pract 2009, 7:15. 10.1186/1897-4287-7-15, 2744911, 19698175.
16. Roshanai AH, Rosenquist R, Lampic C, Nordin K. Does enhanced information at cancer genetic counseling improve counselees' knowledge, risk perception, satisfaction and negotiation of information to at-risk relatives?--a randomized study. Acta Oncol 2009, 48:999-1009. 10.1080/02841860903104137, 19636983.
17. Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 2003, 21:1675-1681. 10.1200/JCO.2003.09.052, 12721241.
18. Gronau KA, Semple JL. A guide to establishing the risk for breast cancer in the plastic surgery patient. Ann Plast Surg 2000, 45:554-559. 10.1097/00000637-200045050-00017, 11092370.
19. Mitchell G, Ardern-Jones A, Kissin Mchir M, Taylor R, Eeles RA. A paradox: urgent BRCA genetic testing. Fam Cancer 2001, 1:25-29. 10.1023/A:1011570302078, 14574012.
20. van Sprundel TC, Schmidt MK, Rookus MA, Brohet R, van Asperen CJ, Rutgers EJ, Van't Veer LJ, Tollenaar RA. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer 2005, 93:287-292. 10.1038/sj.bjc.6602703, 2361560, 16052221.
21. McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH, Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Sellers TA, Hartmann LC. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001, 19:3938-3943.
22. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB, Harris EL, Rolnick S, Pardee R, Husson G, Macedo A, Fletcher SW. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 2005, 23:4275-4286. 10.1200/JCO.2005.10.080, 15795415.
23. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010, 28:222-231. 10.1200/JCO.2009.22.7991, 2815712, 19996031.
24. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Isaacs C, DeMarco T, Halbert CH, Pennanen M, Finch C. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005, 14:1003-1007. 10.1158/1055-9965.EPI-03-0545, 15824179.
25. Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22:1823-1829. 10.1200/JCO.2004.04.086, 15067026.
26. Schlich-Bakker KJ, ten Kroode HF, Ausems MG. A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 2006, 62:13-20. 10.1016/j.pec.2005.08.012, 16242293.
27. Schlich-Bakker KJ, Warlam-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF. Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer 2006, 42:2722-2728. 10.1016/j.ejca.2006.05.032, 16949277.
28. Schlich-Bakker KJ, Ausems MG, Schipper M, ten Kroode HF, Warlam-Rodenhuis CC, van den Bout J. BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat 2008, 109:507-514. 10.1007/s10549-007-9680-y, 2668630, 17674198.
29. Hahn DEE, Bleiker EMA, Aaronson NK, Valdimarsdottir HB, Verhoef S. Experiences with rapid genetic counseling and testing in newly diagnosed breast cancer patients [abstract]. Psychooncology 2006, 15:S261.
30. Frost MH, Slezak JM, Tran NV, Williams CI, Johnson JL, Woods JE, Petty PM, Donohue JH, Grant CS, Sloan JA, Sellers TA, Hartmann LC. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol 2005, 23:7849-7856. 10.1200/JCO.2005.09.233, 16204003.
31. Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu IL, Altschuler A, Rolnick SJ, Harris EL, Greene SM, Elmore JG, Emmons KM, Fletcher SW. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 2006, 24:1350-1356. 10.1200/JCO.2005.01.9901, 16549829.
32. Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 2007, 25:285-291. 10.1200/JCO.2006.07.3890, 17159191.
33. Reavey P, McCarthy CM. Update on breast reconstruction in breast cancer. Curr Opin Obstet Gynecol 2008, 20:61-67. 10.1097/GCO.0b013e3282f2329b, 18197008.
34. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 2001, 1:2. 10.1186/1471-2288-1-2, 32201, 11336663.
35. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997, 336:1409-1415. 10.1056/NEJM199705153362002, 9145677.
36. The Dutch Association of Comprehensive Cancer Centres - Breast Cancer Guideline 1.1. , http://www.oncoline.nl
37. Piantadosi S. Clinical Trials: A Methodologic Perspective 1997, New York: John Wiley & Sons.
38. Van Riel E, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJ, Ausems MG. BRCA testing of breast cancer patients: medical specialists' referral patterns, knowledge and attitudes to genetic testing. Eur J Cancer Care (Engl) 2010, 19:369-376. 10.1111/j.1365-2354.2008.01065.x, 19659662.
39. Ardern-Jones A, Kenen R, Eeles R. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. Eur J Cancer Care (Engl) 2005, 14:272-281. 10.1111/j.1365-2354.2005.00574.x, 15952973.
40. Lerman C, Lustbader E, Rimer B, Daly M, Miller S, Sands C, Balshem A. Effects of individualized breast cancer risk counseling: a randomized trial. J Natl Cancer Inst 1995, 87:286-292. 10.1093/jnci/87.4.286, 7707420.
41. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005, 23:6890-6898. 10.1200/JCO.2005.02.626, 16129845.
42. Valdimarsdottir HB, Bovbjerg DH, Dash KM, Holland JC, Osborne MP, Miller DG. Psychological distress in women with a familial risk of breast cancer. Psychooncology 1995, 4:133-141.
43. Watson M, Duvivier V, Wade Walsh M, Ashley S, Davidson J, Papaikonomou M, Murday V, Sacks N, Eeles R. Family history of breast cancer: what do women understand and recall about their genetic risk?. J Med Genet 1998, 35:731-738. 10.1136/jmg.35.9.731, 1051425, 9733031.
44. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
45. de Bock GH, Bonnema J, Zwaan RE, van de Velde CJ, Kievit J, Stiggelbout AM. Patient's needs and preferences in routine follow-up after treatment for breast cancer. Br J Cancer 2004, 90:1144-1150. 10.1038/sj.bjc.6601655, 2409648, 15026793.
46. Turner J, Kelly B, Swanson C, Allison R, Wetzig N. Psychosocial impact of newly diagnosed advanced breast cancer. Psychooncology 2005, 14:396-407. 10.1002/pon.856, 15386758.
47. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997, 27:363-370. 10.1017/S0033291796004382, 9089829.
48. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979, 41:209-218.
49. Brom D, Kleber RJ. De Schok Verwerkingslijst [The Impact of Event Scale]. Ned Tijdschr Psych 1985, 41:164-168.
50. Holmes-Rovner M, Kroll J, Schmitt N, Rovner DR, Breer ML, Rothert ML, Padonu G, Talarczyk G. Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making 1996, 16:58-64. 10.1177/0272989X9601600114, 8717600.
51. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making 1995, 15:25-30.
52. Koedoot N, Molenaar S, Oosterveld P, Bakker P, de Graeff A, Nooy M, Varekamp I, de Haes H. The decisional conflict scale: further validation in two samples of Dutch oncology patients. Patient Educ Couns 2001, 45:187-193. 10.1016/S0738-3991(01)00120-3, 11722854.
53. Claes E, Evers-Kiebooms G, Boogaerts A, Decruyenaere M, Denayer L, Legius E. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients. Am J Med Genet A 2003, 116A:11-19. 10.1002/ajmg.a.10868, 12476445.
54. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
55. Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996, 14:2756-2768.
56. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.